ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These findings verify CML LSCs are not absolutely dependent on BCR-ABL activity for their survival, and may determine disease persistence, highlighting those patients who are at high risk of molecular recurrence on TKI withdrawal [6, 7].